Portland biotech firm ImmuCell completes $20 million expansion

Biotech firm ImmuCell Corp. of Portland has completed construction on a $20 million, pharmaceutical-grade factory that could help reduce the amount of antibiotics used in the dairy industry, Portland Press Herald reports.

The facility is designed to produce nisin, an antibacterial peptide that ImmuCell plans to sell in purified form as a natural alternative to antibiotics for treating a disease that afflicts lactating dairy cows.

If ImmuCell succeeds in obtaining U.S. Food and Drug Administration approval, the product would give it a competitive edge in the bovine health industry. Completing the production facility is a major step toward obtaining that approval.
Read full story
Immucell Press release Nov 2017

Related Posts

Portland startup Marin Skincare launches lobster-based lip treatment

Portland startup Marin Skincare, known for its “lobster lotion,” is expanding that product line to include lip treatments.  Founded out of the University...

20 November 2023

UMaine scientists use eDNA to enhance river herring recovery research in Penobscot River

University of Maine researchers are seeking to gain more insight into river herring recovery in the Penobscot River using a novel...

16 November 2023

FocusMaine co-founder named group’s next president

Nearly a decade after Andrea Cianchette Maker joined forces with Michael Dubyak to launch FocusMaine, Maker will lead the organization as...

15 November 2023